Skip to main
DVAX
DVAX logo

Dynavax Technologies (DVAX) Stock Forecast & Price Target

Dynavax Technologies (DVAX) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 33%
Buy 44%
Hold 11%
Sell 0%
Strong Sell 11%

Bulls say

Dynavax Technologies Corp has demonstrated strong financial performance, with HEPLISAV-B sales increasing by 39% year-over-year in the fourth quarter of 2024, totaling $71.1 million, and a total FY24 revenue of $268.4 million, reflecting a 26% increase. The company's strategic positioning in the hepatitis B vaccination market, which is projected to exceed $900 million by 2030, along with an anticipated market share of at least 60%, underscores its potential for sustained growth. Additionally, Dynavax's commitment to a significant increase in its share repurchase program to $400 million indicates confidence in its financial health and future profitability.

Bears say

Dynavax Technologies Corp faces significant risks that contribute to a negative outlook on its stock. The company may encounter challenges in its clinical development pipeline, with potential failures to meet efficacy endpoints or adverse reactions that could hinder approval and commercialization. Additionally, Dynavax's reliance on limited revenue streams from its existing products, combined with ongoing regulatory and litigation risks, as well as a history of financial losses without a clear path to profitability, underscores concerns regarding its long-term viability in a competitive market.

Dynavax Technologies (DVAX) has been analyzed by 9 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 44% recommend Buy, 11% suggest Holding, 0% advise Selling, and 11% predict a Strong Sell.

This aggregate rating is based on analysts' research of Dynavax Technologies and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Dynavax Technologies (DVAX) Forecast

Analysts have given Dynavax Technologies (DVAX) a Buy based on their latest research and market trends.

According to 9 analysts, Dynavax Technologies (DVAX) has a Buy consensus rating as of Jul 23, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20.89, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20.89, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Dynavax Technologies (DVAX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.